First, market competition may not reduce prices as dramatically as some expect
Take-home message: - Semaglutide (Ozempic/Wegovy/Rybelsus) and similar medications for diabetes and weight loss have been linked to an increased risk of a very rare form of blindness, meaning that the chance of developing this form of blindness would still be very rare but not quite as much - The handful of studies done on this link come to different conclusions, with disagreements on how much the risk increases and some studies showing no increase in risk - The problem is that all of these studies rely on incomplete databases of patients, and it is possible that any increase in the risk of developing this form of blindness is actually due to other variables that were not measured and compiled in these databases
Injectable: case reports are sparse
Tolerance protocols: Participants who couldnt tolerate Wegovys maintenance dose could simply lower their dosage
Maintaining healthy nutrition, physical activity, and regular medical follow-up remains important
The platform positions itself as suitable for individuals who haven't achieved their weight loss goals through diet and exercise alone, who want clinician-supervised access without the barriers of traditional in-person visits, and who prefer a cash-pay model that doesn't require insurance navigation